Fate Therapeutics
€2.17
-€0.1-4.49% Friday 07:15
Statistics
Day High
2.17
Day Low
2.17
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
417.93M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Earnings
1NovExpected
Expected EPS
-0.416457
Actual EPS
N/A
People Also Follow
This list is based on the watchlists of people on Stock Events who follow F6T.F. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap4.06B
Bluebird bio
BLUE
Mkt Cap108.22M
Novartis
NVS
Mkt Cap244.75B
Gilead Sciences
GILD
Mkt Cap98.35B
Adaptimmune Therapeutics
ADAP
Mkt Cap324.8M
Allogene Therapeutics
ALLO
Mkt Cap549.96M
Sangamo Therapeutics
SGMO
Mkt Cap176.57M
Biomarin Pharmaceutical
BMRN
Mkt Cap17.36B
Pfizer
PFE
Mkt Cap164.39B
First Trust Indxx NextG
NXTG
Mkt Cap0
Analyst Ratings
6.2€Average Price Target
The highest estimate is €9.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
33%
Hold
67%
Sell
0%
About
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Show more...
CEO
Mr. J. Scott Wolchko
Employees
181
Country
US
ISIN
US31189P1021
WKN
000A1W50M